Discounted Cash Flow Rating

Sell

Return on Equity Rating

Sell

Debt to Equity Rating

Strong Buy

Price to Earnings Rating

Strong Buy

Analyst Rating

Buy

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Buy

Standard Deviation

Neutral

Williams %R

Strong Buy

Average Directional Index

Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Buy

A

Exagen Inc. Common Stock (XGN)

Services-medical Laboratories

https://www.exagen.com

Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.

1261 LIBERTY WAY
VISTA, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

09/19/2019

Market Cap

54,914,944

Shares Outstanding

17,050,000

Weighted SO

17,045,827

Total Employees

N/A

Upcoming Earnings

11/11/2024

Similar Tickers

FONR --.--%

BNR --.--%

SERA --.--%

OLK --.--%

LMDX --.--%

GTH --.--%

CSTL --.--%

SHC --.--%

PMD --.--%

Beta

1.2830

Last Div

0.0000

Range

1.3-3.71

Chg

0.3285

Avg Vol

51932

Mkt Cap

54914944

Exch

NASDAQ

Country

US

Phone

760 560 1501

DCF Diff

1.5391

DCF

-0.0191

Div Yield

0.0000

P/S

0.9692

EV Multiple

-3.7686

P/FV

3.2650

Div Yield %

0.0000

P/E

-3.3161

PEG

-0.4628

Payout

0.0000

Current Ratio

4.3187

Quick Ratio

4.0144

Cash Ratio

2.5915

DSO

75.3900

DIO

45.3038

Op Cycle

120.6938

DPO

36.7286

CCC

83.9652

Gross Margin

0.5913

Op Margin

-0.2790

Pretax Margin

-0.3055

Net Margin

-0.3056

Eff Tax Rate

0.0106

ROA

-0.3511

ROE

-0.7890

ROCE

-0.3965

NI/EBT

1.0003

EBT/EBIT

1.0950

EBIT/Rev

-0.2790

Debt Ratio

0.4391

D/E

1.2312

LT Debt/Cap

0.5300

Total Debt/Cap

0.5518

Int Coverage

7903.0000

CF/Debt

-0.2783

Equity Multi

2.8039

Rec Turnover

4.8415

Pay Turnover

9.9378

Inv Turnover

8.0567

FA Turnover

7.0825

Asset Turnover

1.1491

OCF/Share

-0.3314

FCF/Share

-0.3496

Cash/Share

1.3466

OCF/Sales

-0.1063

FCF/OCF

1.0548

CF Coverage

-0.2783

ST Coverage

-3.3104

CapEx Coverage

-18.2576

Div&CapEx Cov

-18.2576

P/BV

3.2650

P/B

3.2650

P/S

0.9692

P/E

-3.3161

P/FCF

-8.6412

P/OCF

-9.5296

P/CF

-9.5296

PEG

-0.4628

P/S

0.9692

EV Multiple

-3.7686

P/FV

3.2650

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jan 18, 17:00 Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap GlobeNewswire Inc. Jan 07, 12:00 Exagen Inc. Announces Select Preliminary Full-Year 2023 Results and Reaffirms Guidance GlobeNewswire Inc. Jan 07, 12:00 Exagen Inc. Announces Select Preliminary Full-Year 2023 Results and Reaffirms Guidance GlobeNewswire Inc. Jan 07, 12:00 Exagen Inc. Announces Select Preliminary Full-Year 2023 Results and Reaffirms Guidance GlobeNewswire Inc. Jan 07, 12:00 Exagen Inc. Announces Select Preliminary Full-Year 2023 Results and Reaffirms Guidance GlobeNewswire Inc. Jan 07, 12:00 Exagen Inc. Announces Select Preliminary Full-Year 2023 Results and Reaffirms Guidance GlobeNewswire Inc. Jan 07, 12:00 Exagen Inc. Announces Select Preliminary Full-Year 2023 Results and Reaffirms Guidance GlobeNewswire Inc. Jan 07, 12:00 Exagen Inc. Announces Select Preliminary Full-Year 2023 Results and Reaffirms Guidance GlobeNewswire Inc. Jan 07, 12:00 Exagen Inc. Announces Select Preliminary Full-Year 2023 Results and Reaffirms Guidance GlobeNewswire Inc. Jan 07, 12:00 Exagen Inc. Announces Select Preliminary Full-Year 2023 Results and Reaffirms Guidance GlobeNewswire Inc. Jan 07, 12:00 Exagen Inc. Announces Select Preliminary Full-Year 2023 Results and Reaffirms Guidance GlobeNewswire Inc. Jan 07, 12:00 Exagen Inc. Announces Select Preliminary Full-Year 2023 Results and Reaffirms Guidance GlobeNewswire Inc. Jan 07, 12:00 Exagen Inc. Announces Select Preliminary Full-Year 2023 Results and Reaffirms Guidance GlobeNewswire Inc. Jan 07, 12:00 Exagen Inc. Announces Select Preliminary Full-Year 2023 Results and Reaffirms Guidance GlobeNewswire Inc. Jan 07, 12:00 Exagen Inc. Announces Select Preliminary Full-Year 2023 Results and Reaffirms Guidance GlobeNewswire Inc. Jan 04, 16:45 Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2023 GlobeNewswire Inc. Jan 04, 16:45 Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2023 GlobeNewswire Inc. Jan 04, 16:40 Axogen Announces Plan for Leadership Transition with CEO Karen Zaderej to Retire from Company by January 2025 GlobeNewswire Inc. Jan 04, 16:35 Axogen Announces Promotions on Research and Development Team GlobeNewswire Inc. Dec 26, 16:15 Axogen, Inc. Appoints Kathy Weiler to its Board of Directors

Revenue Product Segmentation